Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2016 - 2025)

Historic FCF Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 120.08%.

  • Viridian Therapeutics, Inc.\DE's FCF Margin rose 789485300.0% to 120.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 461.0%, marking a year-over-year increase of 649138300.0%. This contributed to the annual value of 77096.03% for FY2024, which is 181571700.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's FCF Margin stood at 120.08%, which was up 789485300.0% from 100553.33% recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin registered a high of 120.08% during Q3 2025, and its lowest value of 128804.17% during Q1 2025.
  • Moreover, its 5-year median value for FCF Margin was 52844.44% (2023), whereas its average is 44139.27%.
  • Data for Viridian Therapeutics, Inc.\DE's FCF Margin shows a peak YoY increase of 789485300bps (in 2025) and a maximum YoY decrease of -659944400bps (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's FCF Margin stood at 7765.89% in 2021, then tumbled by -320bps to 32640.95% in 2022, then crashed by -62bps to 52844.44% in 2023, then crashed by -93bps to 102008.33% in 2024, then soared by 100bps to 120.08% in 2025.
  • Its FCF Margin was 120.08% in Q3 2025, compared to 100553.33% in Q2 2025 and 128804.17% in Q1 2025.